FDA Approves Gilead's Trodelvy for First-Line Treatment of Triple-Negative Breast Cancer
Claire Weston
The FDA approved Gilead's Trodelvy for first-line triple-negative breast cancer, covering both monotherapy and combination with Merck's Keytruda — the drug's first move from later lines into newly diagnosed patients, reshaping treatment options for the hardest-to-treat breast cancer subtype.
What exactly did the FDA approve?
The agency greenlit two indications at once: Trodelvy as a standalone treatment, and Trodelvy combined with Merck's Keytruda.
This means → doctors now have two first-line pathways, choosing monotherapy or an immunotherapy combination based on the patient.
In plain terms = Trodelvy used to be a last-resort drug; now it can be used as soon as a patient is diagnosed.
Where does the clinical evidence come from?
The monotherapy approval rests on the ASCENT-03 trial; the Keytruda combination draws on the ASCENT-04 / KEYNOTE D-19 trial.
Together, the two trials validated Trodelvy's clinical value in the first-line setting — both as a single agent and paired with an immune checkpoint inhibitor (a class of drugs that helps the immune system recognize cancer cells).
This reflects Gilead's dual-track clinical strategy — separate trials, separate regulatory pathways, one coordinated label expansion.
Why does a first-line option for TNBC matter so much?
Triple-negative breast cancer lacks hormone receptors and the HER2 target, so standard targeted therapies and hormonal treatments are largely ineffective.
This means → these patients historically had very few first-line choices; the new approval directly expands the arsenal available at initial diagnosis.
Trodelvy was already approved for HR-positive / HER2-negative metastatic breast cancer; adding first-line TNBC extends its reach across both treatment lines and breast cancer subtypes.
What does this mean for Gilead and Merck?
For Gilead (GILD), moving Trodelvy from a later-line drug to a first-line drug dramatically widens the eligible patient pool.
For Merck (MRK), Keytruda gains another combination setting, reinforcing its role as the backbone of oncology immunotherapy regimens.
In plain terms = a first-line indication is the commercial dividing line for any cancer drug — the earlier it's used, the more patients it reaches, and the higher the revenue ceiling.
Content is for reference only, not financial advice.